Peanut Allergy accounts for the majority of severe food-associated allergic reactions. It is strictly an IgE-mediated type I hypersensitivity reaction. In this response, specific IgE antibodies to peanuts bind to high-affinity receptors on mast cells and basophils which further produce various cytokines and chemokines that attract other inflammatory cells and contribute to the later stages of an IgE-mediated allergic response. At present, Peanut Allergy has been increasing in children.
Currently, the Peanut Allergy treatment domain constitutes an active pipeline with more than 15+ drugs that are under different phases of development.
DelveInsight adds a new edition to its newsletter series that pivots around the Peanut Allergy space. The newsletter offers a complete picture of the Peanut Allergy market landscape, ongoing clinical trials, pipeline therapies that are expected to transform the Peanut Allergy market in the coming decade. Gain rich insights into Peanut Allergy epidemiology details, current treatment therapies, details of the latest news and happenings, mergers and collaborations, critical pharmaceuticals involved, licensing deals along with events and top-level conferences taking place in the Peanut Allergy field.
Interested in knowing more about what upcoming years hold for the Peanut Allergy market and how pharma companies are working to push the drug development? Download our Newsletter by simply filling up the form towards the right.
Subscribe to our mailing list and stay informed about all the recent breakthroughs in the Peanut Allergy Market Outlook.
Know more about What's covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Epidemiological trends
- Treatment approaches
- R&D in the field
- Top conferences
- News Flash
- Recent Research Activities
- Support from International organizations
- Market insights
- Collaborations and deals in the domain